X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 16.0 14.4 111.3% View Chart
P/BV x 4.1 3.8 108.1% View Chart
Dividend Yield % 0.4 0.3 119.5%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
GLENMARK PHARMA
Mar-17
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs895993 90.1%   
Low Rs622729 85.3%   
Sales per share (Unadj.) Rs254.6325.5 78.2%  
Earnings per share (Unadj.) Rs39.339.3 100.0%  
Cash flow per share (Unadj.) Rs46.648.7 95.7%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.30.2 141.9%  
Book value per share (Unadj.) Rs160.0159.2 100.5%  
Shares outstanding (eoy) m585.88282.17 207.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.6 112.6%   
Avg P/E ratio x19.321.9 88.1%  
P/CF ratio (eoy) x16.317.7 92.0%  
Price / Book Value ratio x4.75.4 87.7%  
Dividend payout %6.45.1 125.1%   
Avg Mkt Cap Rs m444,390242,991 182.9%   
No. of employees `00014.013.0 107.8%   
Total wages/salary Rs m17,67816,408 107.7%   
Avg. sales/employee Rs Th10,667.87,083.9 150.6%   
Avg. wages/employee Rs Th1,264.31,265.4 99.9%   
Avg. net profit/employee Rs Th1,645.8855.1 192.5%   
INCOME DATA
Net Sales Rs m149,15791,857 162.4%  
Other income Rs m1,159374 310.2%   
Total revenues Rs m150,31692,230 163.0%   
Gross profit Rs m34,34320,367 168.6%  
Depreciation Rs m4,2762,644 161.8%   
Interest Rs m6672,373 28.1%   
Profit before tax Rs m30,55815,724 194.3%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m7,5973,827 198.5%   
Profit after tax Rs m23,01211,088 207.5%  
Gross profit margin %23.022.2 103.8%  
Effective tax rate %24.924.3 102.1%   
Net profit margin %15.412.1 127.8%  
BALANCE SHEET DATA
Current assets Rs m92,06268,746 133.9%   
Current liabilities Rs m66,22327,027 245.0%   
Net working cap to sales %17.345.4 38.1%  
Current ratio x1.42.5 54.7%  
Inventory Days Days10685 124.7%  
Debtors Days Days6896 70.8%  
Net fixed assets Rs m62,91924,132 260.7%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m93,13344,643 208.6%   
Net worth Rs m93,71944,925 208.6%   
Long term debt Rs m1,81445,363 4.0%   
Total assets Rs m162,494117,639 138.1%  
Interest coverage x46.87.6 613.7%   
Debt to equity ratio x01.0 1.9%  
Sales to assets ratio x0.90.8 117.6%   
Return on assets %14.611.4 127.4%  
Return on equity %24.624.7 99.5%  
Return on capital %32.719.1 171.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83856,152 135.1%   
Fx outflow Rs m30,2248,084 373.9%   
Net fx Rs m45,61348,068 94.9%   
CASH FLOW
From Operations Rs m32,7866,574 498.7%  
From Investments Rs m-17,870-7,124 250.9%  
From Financial Activity Rs m-19,1535,432 -352.6%  
Net Cashflow Rs m-4,2391,992 -212.7%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  FULFORD INDIA  NATCO PHARMA  DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS